Influvac TC

**Influvac TC** was an investigational and formerly authorized **MDCK cell culture-derived trivalent inactivated influenza subunit vaccine** developed initially by Solvay Pharmaceuticals and subsequently by Abbott Biologicals. It contained purified influenza-virus surface antigens, principally hemagglutinin and neuraminidase, from annually selected influenza A H1N1, influenza A H3N2, and influenza B strains. Administered intramuscularly, it was intended to induce strain-specific neutralizing and hemagglutination-inhibiting antibody responses that prevent seasonal influenza. The program was evaluated in adult and elderly clinical studies, including Phase 3 lot-consistency and non-inferiority testing versus egg-derived Influvac, but was discontinued. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01013675))

Brand names

Influvac TC

Other names

cell-based trivalent influenza virus vaccinecell culture-derived trivalent subunit influenza vaccinecell-derived influenza vaccinecell-derived trivalent subunit influenza vaccine